BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Apr 11, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Qnexa phentermine/topiramate: Extension study additional data

Additional data from the double-blind, 52-week SEQUEL (OB-305) extension study of the 56-week Phase III CONQUER (OB-303) trial in 675 obese or overweight patients showed that in patients with baseline hypertension (n=345), both doses of once-daily oral Qnexa phentermine/topiramate (7.5 mg/46 mg or 15 mg/92 mg) significantly reduced the number of antihypertensive medications required by 9.8% and 18.9%, respectively, vs. a gain of 4.2% for placebo (p=0.0012). In all patients, mid- and high-dose Qnexa reduced mean systolic blood...

Read the full 370 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >